Navigation Links
Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
Date:2/21/2008

Diseases Division, where she initiated and led a number of preclinical and clinical development programs. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, University of Bath, U.K. Dr. Gowen has been honored with a number of research awards and prizes, has authored more than 125 peer-reviewed publications, reviews and book chapters, and holds five patents. She received her Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. AEG40826, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, is expected to enter Phase 1 clinical trials for the treatment of cancer in early 2008. In addition, HGS has substantial financial rights to certain products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2007 Financial Results
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
4. Human Genome Sciences and Xencor Announce Antibody Collaboration
5. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
6. Stemagen First to Create Cloned Human Embryos From Adult Cells
7. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
8. International team identifies 480 genes that control human cell division
9. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
10. Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board
11. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... of sequencing technologies, and their applications. Current large ... companies developing them. Various applications of sequencing are ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... , September 2, 2015 ... the winners of the 2015 BeHEARD science challenge, a ... offers rare disease researchers, access to the latest life ... its drug repositioning and pathway analytics capability to support ... Nation Foundation in the study of Niemann-Pick Disease Type ...
(Date:9/2/2015)... 2015 Australian prostate cancer technology company Minomic ... prize recognising ,outstanding, science that uses its patented antibody. ... a novel prostate cancer diagnostic test known as MiCheck® ... taking out the peer-reviewed Australian Museum Eureka Science Prize ... This prize is awarded for ground breaking research ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3
... Clinical and Commercial Adoption of the ... Axxent(R) Electronic Brachytherapy System, FREMONT, Calif., ... Brachytherapy System, a proprietary cancer treatment,platform that utilizes X-rays ... today announced that it will,present at the 26th Annual ...
... BioMarin will Continue to Manufacture; Genzyme will Continue to Market ... ... NOVATO, Calif. and CAMBRIDGE, Mass., Jan. 3 ,BioMarin Pharmaceutical ... ) announced today a restructuring of their joint venture,regarding Aldurazyme(R) ...
... Calif., Jan. 3 Thoratec,Corporation (Nasdaq: THOR ... disease, said today that it will be participating ... 9., Gary Burbach, president and chief executive ... at 8:30 a.m., Pacific Standard Time (11:30,a.m., Eastern ...
Cached Biology Technology:Xoft to Present at the 26th Annual JPMorgan Healthcare Conference 2BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 2BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 4BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 5
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon ... data. Crossmatch is a world leader in multi-factor ... expertise are helping federal agencies and commercial organizations ...   "The vast majority of network ...
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... at the time we are conceived set the course for ... of a new study based on an "experiment of nature" ... DNA the genetic blueprint that determines our make-up ... and 50% from our fathers. Apart from the occasional mutation, ...
... that meshes existing data to produce a clearer ... stimuli. Using this new method, Whitehead Institute and ... toxicity to identify genes and pathways that can ... protein in brain cells are a hallmark of ...
... sleep is a risk: foraging for food, mingling with ... snoozing. How, then, has this seemingly life-threatening behavior ... new study by scientists at North Carolina State University ... sleep, although the sleep comes in widely variable amounts ...
Cached Biology News:'Experiment of nature' examines how mother's diet may impact on child's health 2'Experiment of nature' examines how mother's diet may impact on child's health 3Calculating gene and protein connections in a Parkinson's disease model 2Calculating gene and protein connections in a Parkinson's disease model 3Calculating gene and protein connections in a Parkinson's disease model 4NC State study finds genes important to sleep 2
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... Ideal for hand-held applications or for use ... with a hand-held eight-port disposable manifold provides ... a multi-channel pipette. The StatMatic II can ... sizes and can completely fill a microplate ...
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
Biology Products: